These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605 [TBL] [Abstract][Full Text] [Related]
3. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein. Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845 [TBL] [Abstract][Full Text] [Related]
4. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231 [TBL] [Abstract][Full Text] [Related]
5. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Neely AN; Holder IA; Wiener-Kronish JP; Sawa T Burns; 2005 Mar; 31(2):153-8. PubMed ID: 15683685 [TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the specific activity of hyperimmune anti-Pseudomonas aeruginosa human plasma in an experiment]. Podgornaia LG; Shinkarenko AA; Krokhina MA; Dziuban NF; D'iachenko VF Patol Fiziol Eksp Ter; 1987; (2):70-2. PubMed ID: 3112715 [No Abstract] [Full Text] [Related]
7. Serologic and protective cross-reactivity of antisera to Pseudomonas aeruginosa extracellular slime glycolipoprotein. Yushkova NA; Kholodkova EV; Korobova TS; Stanislavsky ES Acta Microbiol Hung; 1986; 33(2):147-56. PubMed ID: 3101393 [TBL] [Abstract][Full Text] [Related]
8. Effect of active and passive immunization on the development of experimental Pseudomonas aeruginosa pyelonephritis in mice. Petit JC; Sicard D; Bayo S; Daguet GL Can J Microbiol; 1981 Jan; 27(1):93-7. PubMed ID: 6783287 [TBL] [Abstract][Full Text] [Related]
9. [Immunogenic properties of the liposomal form of Pseudomonas aeruginosa anatoxin]. Minukhin VV; Brodinova NS; Tsyganenko AIa; Ivanova NN; Vasil'chenko VN; Sennikov GA Vestn Akad Med Nauk SSSR; 1990; (8):44-7. PubMed ID: 2125778 [TBL] [Abstract][Full Text] [Related]
10. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines. Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018 [TBL] [Abstract][Full Text] [Related]
11. [Experimental infection of immunized mice homologous and heterologous serotypes with Pseudomonas aeruginosa]. Vidal G; Mynard MC Ann Inst Pasteur (Paris); 1972 Jun; 122(6):1129-35. PubMed ID: 4627762 [No Abstract] [Full Text] [Related]
12. [Protective effect of Pseudomonas-specific immunoglobulin from the rabbit and of active immunization in experimental Pseudomonas sepsis in mice]. Trautmann M; Brückner O; Hahn H Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Jul; 252(3):370-83. PubMed ID: 6215803 [TBL] [Abstract][Full Text] [Related]
13. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Weimer ET; Ervin SE; Wozniak DJ; Mizel SB Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586 [TBL] [Abstract][Full Text] [Related]
14. Induction in mice of cell-mediated immunity to Pseudomonas aeruginosa by high molecular weight polysaccharide and vinblastine. Pier GB; Markham RB J Immunol; 1982 May; 128(5):2121-5. PubMed ID: 6174622 [TBL] [Abstract][Full Text] [Related]
15. [Passive immunotherapy for treatment of endobronchitis in cystic fibrosis]. Moss RB Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():42-6; discussion 47. PubMed ID: 8499750 [TBL] [Abstract][Full Text] [Related]
16. Intratracheal immunization with pili protein protects against mortality associated with Pseudomonas aeruginosa pneumonia in mice. Ohama M; Hiramatsu K; Miyajima Y; Kishi K; Nasu M; Kadota J FEMS Immunol Med Microbiol; 2006 Jun; 47(1):107-15. PubMed ID: 16706793 [TBL] [Abstract][Full Text] [Related]
17. Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa. Cachia PJ; Hodges RS Biopolymers; 2003; 71(2):141-68. PubMed ID: 12767116 [TBL] [Abstract][Full Text] [Related]
18. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization. Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420 [TBL] [Abstract][Full Text] [Related]
19. Active and passive immunity against Pseudomonas aeruginosa with a ribosomal vaccine and antiserum in C3H/HeJ mice. Lieberman MM; Ayala E J Immunol; 1983 Jul; 131(1):1-3. PubMed ID: 6408166 [No Abstract] [Full Text] [Related]
20. The role of cytophilic IgG3 antibody in T cell-mediated resistance to infection with the extracellular bacterium, Pseudomonas aeruginosa. Markham RB; Pier GB; Schreiber JR J Immunol; 1991 Jan; 146(1):316-20. PubMed ID: 1898604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]